DENKHAUS DONALD A 4
4 · CATALYST PHARMACEUTICALS, INC. · Filed Dec 10, 2025
Insider Transaction Report
Form 4
DENKHAUS DONALD A
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2025-12-08+1,413→ 497,439 total - Exercise/Conversion
Restricted Stock Units
2025-12-08−1,413→ 179,497 total→ Common Stock (1,413 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vested in equal tranches, 1/3rd on December 8, 2024, 1/3rd on December 8, 2025 and 1/3rd on December 8, 2026.
- [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 8, 2025.